These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19145434)

  • 1. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.
    Bex A; van der Veldt AA; Blank C; van den Eertwegh AJ; Boven E; Horenblas S; Haanen J
    World J Urol; 2009 Aug; 27(4):533-9. PubMed ID: 19145434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
    Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
    Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.
    Lane BR; Derweesh IH; Kim HL; O'Malley R; Klink J; Ercole CE; Palazzi KL; Thomas AA; Rini BI; Campbell SC
    Urol Oncol; 2015 Mar; 33(3):112.e15-21. PubMed ID: 25532471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients.
    Seidel C; Fenner M; Merseburger AS; Reuter C; Ivanyi P; Länger F; Ganser A; Grünwald V
    World J Urol; 2011 Jun; 29(3):355-60. PubMed ID: 21258806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performing cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective.
    Shaw GL; Hussain M; Nair R; Bycroft J; Beltran L; Green JS; Powles T; Peters JL
    Urol Int; 2012; 89(1):83-8. PubMed ID: 22614181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ.
    Bex A; Blank C; Meinhardt W; van Tinteren H; Horenblas S; Haanen J
    Urology; 2011 Oct; 78(4):832-7. PubMed ID: 21802123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study.
    Stroup SP; Raheem OA; Palazzi KL; Liss MA; Mehrazin R; Kopp RP; Patel N; Cohen SA; Park SK; Patterson AL; Kane CJ; Millard F; Derweesh IH
    Urology; 2013 Apr; 81(4):805-11. PubMed ID: 23414694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of T4 renal cell carcinoma after a neoadjuvant targeted therapy using sunitinib: report of a case.
    Ueda K; Noguchi M; Suekane S; Moriya F; Nagayoshi R; Ejima K; Momozono K; Matsuoka K
    Kurume Med J; 2011; 58(3):95-8. PubMed ID: 22531125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy.
    Dall'Oglio MF; Sousa-Canavez JM; Tanno FY; Tiseo BC; Crippa A; Dos Reis ST; Leite KR; Srougi M
    Int Braz J Urol; 2011; 37(2):180-5; discussion 185-6. PubMed ID: 21557834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
    Méjean A; Ravaud A; Thezenas S; Colas S; Beauval JB; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Beisland C; Aitchison M; Oudard S; Patard JJ; Theodore C; Chevreau C; Laguerre B; Hubert J; Gross-Goupil M; Bernhard JC; Albiges L; Timsit MO; Lebret T; Escudier B
    N Engl J Med; 2018 Aug; 379(5):417-427. PubMed ID: 29860937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
    Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
    Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.
    Ansari J; Doherty A; McCafferty I; Wallace M; Deshmukh N; Porfiri E
    Clin Genitourin Cancer; 2009 Aug; 7(2):E39-41. PubMed ID: 19692322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study.
    Xu WH; Wang J; Huo DZ; Yin GC; Cao DL; Shi GH; Qu YY; Ye DW; Zhang HL
    Med Sci Monit; 2019 Nov; 25():8984-8994. PubMed ID: 31769434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib.
    Welsh SJ; Thompson N; Warren A; Priest AN; Barrett T; Ursprung S; Gallagher FA; Zaccagna F; Stewart GD; Fife KM; Matakidou A; Machin AJ; Qian W; Ingleson V; Mullin J; Riddick ACP; Armitage JN; Connolly S; Eisen TGQ
    BJU Int; 2022 Aug; 130(2):244-253. PubMed ID: 34549873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study.
    Bamias A; Tzannis K; Papatsoris A; Oudard S; Beuselinck B; Escudier B; Liontos M; Elaidi TR; Chrisofos M; Stravodimos K; Anastasiou I; Mitropoulos D; Deliveliotis C; Constantinides C; Dimopoulos MA; Bamia C
    Clin Genitourin Cancer; 2014 Oct; 12(5):373-83. PubMed ID: 24819319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.
    Silberstein JL; Millard F; Mehrazin R; Kopp R; Bazzi W; DiBlasio CJ; Patterson AL; Downs TM; Yunus F; Kane CJ; Derweesh IH
    BJU Int; 2010 Nov; 106(9):1270-6. PubMed ID: 20394613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged response to cytoreductive surgery and sunitinib in an elderly patient with synchronous multiple metastases from renal cell carcinoma.
    Locatelli MC; Miedico A; D'Antona A; Longo G; Maggioni M; Maggioni A; Tombolini P; Tabiadon D
    Tumori; 2010; 96(3):478-82. PubMed ID: 20845812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Graham J; Bhindi B; Heng DYC
    Curr Opin Urol; 2019 Sep; 29(5):507-512. PubMed ID: 31305275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.